These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 19820367

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.
    Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M, Kawarabayashi T.
    Br J Cancer; 2005 Mar 28; 92(6):1098-103. PubMed ID: 15756272
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Apoptosis as a possible candidate mechanism for removal of tamoxifen-related endometrial cells with KRAS mutations.
    Tsujioka H, Hachisuga T, Hikita S, Ueda T, Yotsumoto F, Shirota K, Yoshizato T, Kawarabayashi T, Kuroki M, Miyamoto S.
    Anticancer Res; 2010 Aug 28; 30(8):3119-23. PubMed ID: 20871029
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I, Takahashi S, O'uchi K, Akimoto N, Hanari K, Ogaki Y, Enatsu YH, Takigawa A, Takaya H, Tanaka A, Kaseki H, Yamada T.
    Gan To Kagaku Ryoho; 2010 Feb 28; 37(2):279-83. PubMed ID: 20154485
    [Abstract] [Full Text] [Related]

  • 15. The value of transvaginal ultrasonography in the prediction of endometrial pathologies in asymptomatic postmenopausal breast cancer tamoxifen-treated patients.
    Markovitch O, Tepper R, Fishman A, Shapira J, Aviram R, Cohen I.
    Gynecol Oncol; 2004 Dec 28; 95(3):456-62. PubMed ID: 15581946
    [Abstract] [Full Text] [Related]

  • 16. Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan.
    Matsuyama Y, Tominaga T, Nomura Y, Koyama H, Kimura M, Sano M, Miura S, Takashima S, Mitsuyama S, Ueo H, Ohashi Y.
    Ann Oncol; 2000 Dec 28; 11(12):1537-43. PubMed ID: 11205460
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Endometrial and other primary cancers after tamoxifen treatment of breast cancer -- results of retrospective cohort study.
    Ursic Vrscaj M, Kovacic J, Bebar S, Djurisic A, Fras PA, Robic V.
    Eur J Obstet Gynecol Reprod Biol; 2001 Mar 28; 95(1):105-10. PubMed ID: 11267730
    [Abstract] [Full Text] [Related]

  • 19. Uterine neoplasms in patients treated with tamoxifen.
    Silva EG, Tornos C, Malpica A, Mitchell MF.
    J Cell Biochem Suppl; 1995 Mar 28; 23():179-83. PubMed ID: 8747394
    [Abstract] [Full Text] [Related]

  • 20. The effects of tamoxifen treatment on the endometrium.
    Daniel Y, Inbar M, Bar-Am A, Peyser MR, Lessing JB.
    Fertil Steril; 1996 Jun 28; 65(6):1083-9. PubMed ID: 8641477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.